drugset
drugset / Trial / NCT07223216

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216 ↗

Phase 1 Active not recruiting 80 enrolled Biomea Fusion Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese Participants.

Timeline

Start
2025-10-23
Primary completion
2026-05
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject BMF-650 Small molecule 10 mg Oral
Subject BMF-650 Small molecule 25 mg Oral
Subject BMF-650 Small molecule 50 mg Oral
Subject BMF-650 Small molecule 100 mg Oral
Subject BMF-650 Small molecule 200 mg Oral
Subject BMF-650 Small molecule 300 mg Oral
Subject BMF-650 Small molecule 400 mg Oral

Indications

obesity disorder